openPR Logo
Press release

Primary Hyperoxaluria Pipeline and Clinical Trials Assessment: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Alnylam Pharmaceuticals, Inc., Genentech, Inc., Dicerna Pharmaceuticals, Inc., Pfizer Inc., Zhejiang Tianxin Pharmaceutica

05-19-2024 08:41 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Primary Hyperoxaluria Pipeline and Clinical Trials

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Primary Hyperoxaluria pipeline constitutes 8+ key companies continuously working towards developing 8+ Primary Hyperoxaluria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Primary Hyperoxaluria Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Hyperoxaluria Market.

The Primary Hyperoxaluria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Primary Hyperoxaluria Pipeline Report: https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Primary Hyperoxaluria treatment therapies with a considerable amount of success over the years.
• Primary Hyperoxaluria companies working in the treatment market are Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others, are developing therapies for the Primary Hyperoxaluria treatment
• Emerging Primary Hyperoxaluria therapies in the different phases of clinical trials are- CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others are expected to have a significant impact on the Primary Hyperoxaluria market in the coming years.
• In September 2022, Novo Nordisk presented Nedosiran to the FDA in the United States for regulatory consideration.
• In June 2023, Chinook Therapeutics announced findings from a Phase I trial of CHK-336, an oral small molecule LDHA inhibitor being developed for primary hyperoxaluria (PH) and other kidney stone conditions. This placebo-controlled, single-center, randomized, double-blind study assessed the tolerability, safety, and pharmacokinetics (PK) of CHK-336 in 104 healthy volunteers (HV).
• In February 2022, Dicerna Pharmaceuticals, Inc. has commenced a Phase II open-label multicenter investigation to assess the safety, pharmacokinetics, and effectiveness of Nedosiran in pediatric patients ranging from birth to 11 years old, specifically those diagnosed with primary hyperoxaluria and possessing relatively preserved renal function.

Primary Hyperoxaluria Overview
Primary Hyperoxaluria (PH) is a rare genetic disorder characterized by the overproduction of oxalate, a substance that is normally eliminated through the kidneys in the urine. In individuals with Primary Hyperoxaluria, there is a defect in the liver enzymes responsible for breaking down glyoxylate, leading to an accumulation of oxalate in the body.

Get a Free Sample PDF Report to know more about Primary Hyperoxaluria Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Primary Hyperoxaluria Drugs Under Different Phases of Clinical Development Include:
• CHK-336: Chinook Therapeutics
• BBP-711: Cantero Therapeutics
• BMN 255: BioMarin Pharmaceutical, Inc
• Oxabact: OxThera
• Nedosiran: Dicerna Pharmaceuticals, Inc.

Primary Hyperoxaluria Route of Administration
Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Primary Hyperoxaluria Molecule Type
Primary Hyperoxaluria Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Primary Hyperoxaluria Pipeline Therapeutics Assessment
• Primary Hyperoxaluria Assessment by Product Type
• Primary Hyperoxaluria By Stage and Product Type
• Primary Hyperoxaluria Assessment by Route of Administration
• Primary Hyperoxaluria By Stage and Route of Administration
• Primary Hyperoxaluria Assessment by Molecule Type
• Primary Hyperoxaluria by Stage and Molecule Type
DelveInsight's Primary Hyperoxaluria Report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Primary Hyperoxaluria product details are provided in the report. Download the Primary Hyperoxaluria pipeline report to learn more about the emerging Primary Hyperoxaluria therapies at:
https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Primary Hyperoxaluria Therapeutics Market include:
Key companies developing therapies for Primary Hyperoxaluria are - Alnylam Pharmaceuticals, Inc., Genentech, Inc., Dicerna Pharmaceuticals, Inc., Pfizer Inc., Zhejiang Tianxin Pharmaceutical Co., Wuxi Further Pharmaceutical Co Ltd, Tecoland Corporation, Takeda Pharmaceuticals Company Limited, Intellia Therapeutics, Inc., and others.

Primary Hyperoxaluria Pipeline Analysis:
The Primary Hyperoxaluria pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Primary Hyperoxaluria with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxaluria Treatment.
• Primary Hyperoxaluria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Primary Hyperoxaluria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Hyperoxaluria market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Primary Hyperoxaluria drugs and therapies-
https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Primary Hyperoxaluria Pipeline Market Drivers
• Rising Prevalence of Primary hyperoxaluria, increasing demand of disease specific novel treatment are some of the important factors that are fueling the Primary Hyperoxaluria Market.

Primary Hyperoxaluria Pipeline Market Barriers
• However, high cost of treatment and diagnosis for Hyperoxaluria, limited research and development for treatment and other factors are creating obstacles in the Primary Hyperoxaluria Market growth.

Scope of Primary Hyperoxaluria Pipeline Drug Insight
• Coverage: Global
• Key Primary Hyperoxaluria Companies: Chinook Therapeutics, Cantero Therapeutics, BioMarin Pharmaceutical, Inc, OxThera, Dicerna Pharmaceuticals, Inc., and others
• Key Primary Hyperoxaluria Therapies: CHK-336, BBP-711, BMN 255, Oxabact, Nedosiran, and others
• Primary Hyperoxaluria Therapeutic Assessment: Primary Hyperoxaluria current marketed and Primary Hyperoxaluria emerging therapies
• Primary Hyperoxaluria Market Dynamics: Primary Hyperoxaluria market drivers and Primary Hyperoxaluria market barriers

Request for Sample PDF Report for Primary Hyperoxaluria Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Primary Hyperoxaluria Report Introduction
2. Primary Hyperoxaluria Executive Summary
3. Primary Hyperoxaluria Overview
4. Primary Hyperoxaluria- Analytical Perspective In-depth Commercial Assessment
5. Primary Hyperoxaluria Pipeline Therapeutics
6. Primary Hyperoxaluria Late Stage Products (Phase II/III)
7. Primary Hyperoxaluria Mid Stage Products (Phase II)
8. Primary Hyperoxaluria Early Stage Products (Phase I)
9. Primary Hyperoxaluria Preclinical Stage Products
10. Primary Hyperoxaluria Therapeutics Assessment
11. Primary Hyperoxaluria Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Primary Hyperoxaluria Key Companies
14. Primary Hyperoxaluria Key Products
15. Primary Hyperoxaluria Unmet Needs
16 . Primary Hyperoxaluria Market Drivers and Barriers
17. Primary Hyperoxaluria Future Perspectives and Conclusion
18. Primary Hyperoxaluria Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Primary Hyperoxaluria Market https://www.delveinsight.com/report-store/primary-hyperoxaluria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Primary Hyperoxaluria Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Primary Hyperoxaluria Epidemiology https://www.delveinsight.com/report-store/primary-hyperoxaluria-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Primary Hyperoxaluria Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Hyperoxaluria Pipeline and Clinical Trials Assessment: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Alnylam Pharmaceuticals, Inc., Genentech, Inc., Dicerna Pharmaceuticals, Inc., Pfizer Inc., Zhejiang Tianxin Pharmaceutica here

News-ID: 3502532 • Views:

More Releases from DelveInsight Business Research

Breast Cancer Biomarker Market Forecast 2032: FDA, EMA and PDMA Approvals, Epidemiology, Therapies, Companies by DelveInsight | Pfizer, AstraZeneca, Sermonix Pharmaceuticals, Novartis
Breast Cancer Biomarker Market Forecast 2032: FDA, EMA and PDMA Approvals, Epide …
(Albany, USA) DelveInsight's "Breast Cancer Biomarker Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Breast Cancer Biomarker, historical and forecasted epidemiology as well as the Breast Cancer Biomarker market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Breast Cancer Biomarker market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and
Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis 2024: FDA Approvals, C …
(Albany, USA) As per DelveInsight's assessment, globally, Murine Double Minute 2 (MDM2) Inhibitor pipeline constitutes key companies continuously working towards developing Murine Double Minute 2 (MDM2) Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Murine Double Minute 2 (MDM2) Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Murine
Interstitial Lung Disease Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Interstitial Lung Disease Clinical Trials Analysis 2024: FDA Approvals, Pipeline …
(Albany, United States) As per DelveInsight's assessment, globally, Interstitial Lung Disease pipeline constitutes 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Interstitial Lung Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market. The Interstitial Lung Disease
Myopia Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and companies by DelveInsight | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics
Myopia Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechan …
(Albany, USA) As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 10+ pipeline drugs in the Myopia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Myopia Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis

All 5 Releases


More Releases for Primary

Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk
Global Primary Sclerosing Cholangitis Market
The Primary Sclerosing Cholangitis report offers insights into vital aspects like growth,CAGR value, market share and revenue analysis. It evaluates the growth opportunities, threats, market drivers and risks involved. understand the market competition by analyzing the top vendors, with their market profile, revenue, profits, import-export details, and market share. it states the pricing structure, import-export details, supply chain analysis, SWOT analysis to facilitate the key decision-making process. This report helps
Primary Lithium Battery (Primary Lithium Batteries) Industry Analysis by 2025:  …
In its recently published report, QY Research has provided unique insights about global Primary Lithium Battery (Primary Lithium Batteries) market for the given period. One of the main objectives of this report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the global Primary
Primary Cells And Primary Batteries Market Analysis by Production Capacity, Dyna …
This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Primary Cells And Primary Batteries market. Description The Global Primary Cells And Primary Batteries Market report offers a comprehensive evaluation of the Global Primary Cells And Primary Batteries industry. This report evaluates the Global market for " Global Primary Cells And Primary Batteries". The Global Primary Cells
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
01-25-2017 | Health & Medicine
TMR
Global Primary Biliary Cholangitis Treatment Market is Driven by Rise in Inciden …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes